Showing results (271-280 of 314) with videos related to
Sort By:
Pageof 32
European Urology|October 27, 2023
Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 StudyRenu S Eapen, James P Buteau, Price Jackson, et al.European Urology|October 22, 2018
Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic ReviewThomas Van den Broeck, Roderick C N van den Bergh, Nicolas Arfi, et al.Prostate International|August 7, 2019
Report of the third Asian Prostate Cancer study meetingBannakij Lojanapiwat, Ji Youl Lee, Zhu Gang, et al.Nature Communications|November 18, 2020
Author Correction: Transcriptomic and cellular decoding of regional brain vulnerability to neurogenetic disordersJakob Seidlitz, Ajay Nadig, Siyuan Liu, et al.Nature Communications|July 5, 2020
Transcriptomic and cellular decoding of regional brain vulnerability to neurogenetic disordersJakob Seidlitz, Ajay Nadig, Siyuan Liu, et al.Nature Communications|July 21, 2025
Transcriptomic decoding of surface-based imaging phenotypes and its application to pharmacotranscriptomicsChristine Ecker, Charlotte M Pretzsch, Johanna Leyhausen, et al.Asia-Pacific Journal of Clinical Oncology|February 8, 2022
Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statementsEdmund Chiong, Declan G Murphy, Nicholas C Buchan, et al.Journal of Autism and Developmental Disorders|March 10, 2007
Offering to share: how to put heads together in autism neuroimagingMatthew K Belmonte, John C Mazziotta, Nancy J Minshew, et al.The Lancet. Oncology|October 21, 2025
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trialLouise Kostos, James P Buteau, Jing Xie, et al.The Lancet. Oncology|May 17, 2026
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 studyShankar Siva, David Pryor, Jarad Martin, et al.Pageof 32